Actgen Pharma Profile
Key Indicators
- Authorised Capital ₹ 9.00 Cr
as on 31-07-2024
- Paid Up Capital ₹ 9.00 Cr
as on 31-07-2024
- Company Age 16 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 72.00 Cr
as on 31-07-2024
- Revenue 980.20%
(FY 2023)
- Profit 958.83%
(FY 2023)
- Ebitda 958.47%
(FY 2023)
- Net Worth 119.91%
(FY 2023)
- Total Assets -9.05%
(FY 2023)
About Actgen Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.00 Cr and a paid-up capital of Rs 9.00 Cr.
The company has closed loans amounting to ₹72.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Kantilal Hiran and Dariyadevi Hiran serve as directors at the Company.
- CIN/LLPIN
U24239MH2008PTC179859
- Company No.
179859
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Mar 2008
- Date of AGM
01 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Actgen Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kantilal Hiran  | Additional Director | Current | |
| Dariyadevi Hiran | Director | Current |
Financial Performance of Actgen Pharma.
Actgen Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 980.2% increase. The company also saw a substantial improvement in profitability, with a 958.83% increase in profit. The company's net worth Soared by an impressive increase of 119.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Actgen Pharma?
In 2023, Actgen Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sunflower Trading And Investment Pvt LtdActive 35 years 5 monthsKantilal Hiran and Dariyadevi Hiran are mutual person
Charges (Loans)
₹0
₹72.00 Cr
Charges Breakdown by Lending Institutions
- Bank Of India : 72.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jan 2010 | Bank Of India | ₹27.00 Cr | Satisfied |
| 27 Feb 2009 | Bank Of India | ₹27.00 Cr | Satisfied |
| 27 Nov 2008 | Bank Of India | ₹18.00 Cr | Satisfied |
How Many Employees Work at Actgen Pharma?
Actgen Pharma has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Actgen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Actgen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
